

Lisa H Butterfield

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4042750/lisa-h-butterfield-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

9,719
citations

55
h-index

94
g-index

199
ext. papers

11,618
ext. citations

8.9
avg, IF

6.15
L-index

#	Paper	IF	Citations
172	Novel dendritic cell vaccine strategies 2022 , 109-135		
171	Hallmarks of Resistance to Immune-Checkpoint Inhibitors.. <i>Cancer Immunology Research</i> , 2022 , 10, 372-383	8.5	2
170	The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021.. <i>Journal of Translational Medicine</i> , 2022 , 20, 179	8.5	
169	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma 2021 , 9,		2
168	Neoadjuvant Pembrolizumab and High-Dose IFN γ in Resectable Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4195-4204	12.9	3
167	The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020. <i>Journal of Translational Medicine</i> , 2021 , 19, 144	8.5	
166	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2021 , 19, 13	8.5	1
165	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR 2021 , 9,		4
164	Accelerating the development of innovative cellular therapy products for the treatment of cancer. <i>Cytotherapy</i> , 2020 , 22, 239-246	4.8	3
163	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020 , 577, 549-555	50.4	654
162	Adverse childhood experiences (ACEs), cell-mediated immunity, and survival in the context of cancer. <i>Brain, Behavior, and Immunity</i> , 2020 , 88, 566-572	16.6	4
161	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6325-6337	15.9	21
160	Dysregulated NF- κ B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. <i>Cancer Immunology Research</i> , 2020 , 8, 1554-1567	12.5	6
159	Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy 2020 , 8,		5
158	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee 2020 , 8,		6
157	Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	14
156	First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells. <i>Journal of Translational Medicine</i> , 2019 , 17, 271	8.5	11

155	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop 2019 , 7, 131		41
154	Tumor-Derived Fetoprotein Suppresses Fatty Acid Metabolism and Oxidative Phosphorylation in Dendritic Cells. <i>Cancer Immunology Research</i> , 2019 , 7, 1001-1012	12.5	15
153	Multiple antigen-engineered DC vaccines with or without IFN α to promote antitumor immunity in melanoma 2019 , 7, 113		14
152	CD56 CD16 Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon- β <i>Frontiers in Immunology</i> , 2019 , 10, 14	8.4	22
151	Interleukin 32 expression in human melanoma. <i>Journal of Translational Medicine</i> , 2019 , 17, 113	8.5	6
150	The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 2019 , 7, 221		2
149	Melanoma vaccines: clinical status and immune endpoints. <i>Melanoma Research</i> , 2019 , 29, 109-118	3.3	9
148	Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. <i>Cellular Immunology</i> , 2019 , 335, 59-67	4.4	4
147	Prospective Analyses of Cytokine Mediation of Sleep and Survival in the Context of Advanced Cancer. <i>Psychosomatic Medicine</i> , 2018 , 80, 483-491	3.7	16
146	Dendritic Cell-Based Cancer Vaccines. <i>Journal of Immunology</i> , 2018 , 200, 443-449	5.3	138
145	Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. <i>Cancer Prevention Research</i> , 2018 , 11, 429-438	3.2	38
144	Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. <i>Melanoma Research</i> , 2018 , 28, 211-221	3.3	13
143	The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. <i>Seminars in Cancer Biology</i> , 2018 , 52, 12-15	12.7	10
142	High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. <i>Cellular Immunology</i> , 2018 , 323, 9-18	4.4	19
141	Immune oncology, immune responsiveness and the theory of everything 2018 , 6, 50		40
140	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy) 2018 , 6, 69		10
139	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. <i>JCI Insight</i> , 2018 , 3,	9.9	14
138	Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sjögren syndrome. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 423-434	7.4	14

137	Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. <i>Journal of Translational Medicine</i> , 2018 , 16, 184	8.5	18
136	NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018 , 124, 4332-4341	6.4	5
135	Tumor-Derived Fetoprotein Directly Drives Human Natural Killer-Cell Activation and Subsequent Cell Death. <i>Cancer Immunology Research</i> , 2017 , 5, 493-502	12.5	12
134	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2017 , 5, 480-492	12.5	196
133	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017 , 23, 5034-5043	12.9	24
132	Systematic evaluation of immune regulation and modulation 2017 , 5, 21		15
131	Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. <i>Journal of Translational Medicine</i> , 2017 , 15, 39	8.5	7
130	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2017 , 18, 1493-1501	21.7	544
129	Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017 , 7, 112-122	6.4	7
128	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016 2017 , 5, 55		4
127	ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS. <i>Neuro-Oncology</i> , 2017 , 19, vi28-vi28	1	78
126	Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. <i>Cytotherapy</i> , 2017 , 19, 1225-1232	4.8	86
125	Immunotherapy biomarkers 2016: overcoming the barriers 2017 , 5, 29		17
124	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy 2017 , 5, 44		139
123	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations 2016 , 4, 77		68
122	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. <i>Journal of Neuro-Oncology</i> , 2016 , 130, 517-527	4.8	36
121	Cytokine Assays 2016 , 1-11		
120	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule 2016 , 4, 37		

119	Web-based collaborative care intervention to manage cancer-related symptoms in the palliative care setting. <i>Cancer</i> , 2016 , 122, 1270-82	6.4	55
118	Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer 2016 , 4, 24		15
117	Novel technologies and emerging biomarkers for personalized cancer immunotherapy 2016 , 4, 3		146
116	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. <i>Neuro-Oncology</i> , 2016 , 18, 1157-68	1	53
115	Lessons learned from cancer vaccine trials and target antigen choice. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 805-12	7.4	20
114	Dose-response evaluation of broccoli sprout extract sulforaphane (BSE-SFN) in melanoma patients (Pts) with atypical/dysplastic nevi (A/DN).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21022-e21022	2.2	3
113	Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21059-e21059	2.2	
112	Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 1649-1649	2.2	1
111	Prospective Clinical Testing of Regulatory Dendritic Cells in Organ Transplantation. <i>Frontiers in Immunology</i> , 2016 , 7, 15	8.4	32
110	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation 2016 , 4, 76		122
109	Cancer immunotherapy trials: leading a paradigm shift in drug development 2016 , 4, 42		28
108	Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab 2016 , 4, 38		22
107	Dendritic cell control of immune responses. <i>Frontiers in Immunology</i> , 2015 , 6, 42	8.4	14
106	Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. <i>Clinical Cancer Research</i> , 2015 , 21, 286-94	12.9	75
105	Cancer vaccines. <i>BMJ, The</i> , 2015 , 350, h988	5.9	156
104	Preamble to the 2015 SITC immunotherapy biomarkers taskforce 2015 , 3, 8		3
103	Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative	2.2	80
102	Pilot trial of a type I-polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer 2015 , 3,		78

101	Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma 2015 , 3, 32		13
100	Baseline circulating IL-17 predicts toxicity while TGF- β and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma 2015 , 3, 39		200
99	Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- β but Not Observation in Intermediate Risk Melanoma Patients. <i>PLoS ONE</i> , 2015 , 10, e0132745	3.7	8
98	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>Onc Immunology</i> , 2015 , 4, e998538	7.2	101
97	A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. <i>European Urology</i> , 2015 , 68, 365-71	10.2	37
96	Regulatory T Cell Response to Factor VIII in Mothers of Children with Hemophilia Inhibitors. <i>Blood</i> , 2015 , 126, 3512-3512	2.2	
95	Immunologic monitoring of cancer vaccine trials using the ELISPOT assay. <i>Methods in Molecular Biology</i> , 2014 , 1102, 71-82	1.4	7
94	Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2656-6	2.2	135
93	Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. <i>Journal of Translational Medicine</i> , 2014 , 12, 86	8.5	36
92	Tumor-derived alpha-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells 2014 , 2,		78
91	Molecular mimicry of MAGE-A6 and HF-2 epitopes in the induction of antitumor CD8 T-cell responses. <i>Onc Immunology</i> , 2014 , 3, e954501	7.2	13
90	Tumor-derived β fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. <i>Journal of Immunology</i> , 2014 , 193, 5723-32	5.3	45
89	Phase I dendritic cell p53 peptide vaccine for head and neck cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 2433-44	12.9	95
88	Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. <i>Hepatology</i> , 2014 , 59, 1448-58	11.2	30
87	Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 1744-53	27.4	259
86	Web-based stepped collaborative care intervention in the context of advanced cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9522-9522	2.2	3
85	Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. <i>PLoS ONE</i> , 2014 , 9, e87705	3.7	220
84	Measurements of natural killer (NK) cells. <i>Critical Reviews in Oncogenesis</i> , 2014 , 19, 47-55	1.3	1

83	Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation-positive melanoma with metastases to the brain (BRV116521).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9112-TPS9112	2.2	
82	Insights into the Process of Translating Emerging Immunologic Paradigms to Clinical Trial in Patients with Cancer 2014 , 205-219		
81	Ependymomas: development of immunotherapeutic strategies. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 1089-98	4.3	5
80	Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma 2013 , 1, 19		4
79	Melanoma-associated leukoderma - immunology in black and white?. <i>Pigment Cell and Melanoma Research</i> , 2013 , 26, 796-804	4.5	30
78	Dendritic cells in cancer immunotherapy clinical trials: are we making progress?. <i>Frontiers in Immunology</i> , 2013 , 4, 454	8.4	81
77	A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). <i>Clinical Cancer Research</i> , 2013 , 19, 4228-38	12.9	77
76	Peptide vaccine therapy for childhood gliomas. <i>Neurosurgery</i> , 2013 , 60 Suppl 1, 113-9	3.2	8
75	Approaches to Immunologic Monitoring of Clinical Trials 2013 , 663-694		
74	Pitfalls in retrospective analyses of biomarkers: a case study with metastatic melanoma patients. <i>Journal of Immunological Methods</i> , 2012 , 376, 108-12	2.5	15
73	Immunotherapy of cancer in 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2012 , 62, 309-35	220.7	301
72	T cell assays and MIATA: the essential minimum for maximum impact. <i>Immunity</i> , 2012 , 37, 1-2	32.3	117
71	Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). <i>International Journal of Cancer</i> , 2012 , 131, 874-84	7.5	34
70	A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2012 , 61, 783-8	7.4	9
69	Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. <i>OncolImmunology</i> , 2012 , 1, 287-357	7.2	21
68	Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. <i>OncolImmunology</i> , 2012 , 1, 48-55	7.2	121
67	Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10. <i>OncolImmunology</i> , 2012 , 1, 448-457	7.2	25
66	Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-βr TLR-9 agonist and GM-CSF with peptide vaccination. <i>Journal of Immunotherapy</i> , 2012 , 35, 702-10	5	56

65	185 Peptide Vaccine Therapy for Childhood Gliomas Interim Results of a Pilot Study. <i>Neurosurgery</i> , 2012 , 71, E572	3.2	2
64	Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 76-76	2.2	2
63	Comparison of SearchLight and Luminex multiplex assays: A case study of 27 cytokines in 156 melanoma blood serum samples.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 79-79	2.2	
62	Randomized controlled trial of a collaborative care intervention to manage cancer-related symptoms: lessons learned. <i>Clinical Trials</i> , 2011 , 8, 298-310	2.2	19
61	Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo. <i>International Journal of Oncology</i> , 2011 , 39, 245-53	4.4	8
60	Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?. <i>Immunologic Research</i> , 2011 , 50, 235-47	4.3	24
59	SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. <i>Journal of Translational Medicine</i> , 2011 , 9, 155	8.5	24
58	Multiplex serum biomarker assessments: technical and biostatistical issues. <i>Journal of Translational Medicine</i> , 2011 , 9, 173	8.5	35
57	Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. <i>Molecular Therapy</i> , 2011 , 19, 805-14	11.7	32
56	Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. <i>Clinical and Developmental Immunology</i> , 2011 , 2011, 249281		31
55	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. <i>Clinical Cancer Research</i> , 2011 , 17, 3064-76	12.9	87
54	Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. <i>Journal of Clinical Oncology</i> , 2011 , 29, 320-6	2.2	441
53	Isolation, culture and propagation of natural killer cells 2010 , 125-135		0
52	Zinc in innate and adaptive tumor immunity. <i>Journal of Translational Medicine</i> , 2010 , 8, 118	8.5	85
51	Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. <i>Blood</i> , 2010 , 116, 575-83	2.2	55
50	Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study. <i>Journal of Pain and Symptom Management</i> , 2010 , 39, 859-71	4.8	35
49	New approaches to the development of adenoviral dendritic cell vaccines in melanoma. <i>Current Opinion in Investigational Drugs</i> , 2010 , 11, 1399-408		12
48	Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro. <i>Journal of Immunology</i> , 2009 , 183, 7250-8	5.3	28

47	Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. <i>Clinical Cancer Research</i> , 2009 , 15, 1443-51	12.9	120
46	Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 121-33	7.4	29
45	Dendritic Cell Vaccines for Immunotherapy of Cancer: Challenges in Clinical Trials 2009 , 159-172		
44	Next generation of immunotherapy for melanoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3445-55	2.2	185
43	Development of a potency assay for human dendritic cells: IL-12p70 production. <i>Journal of Immunotherapy</i> , 2008 , 31, 89-100	5	42
42	Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. <i>Journal of Immunotherapy</i> , 2008 , 31, 294-309	5	97
41	Alpha-fetoprotein and other tumour-associated antigens for immunotherapy of hepatocellular cancer. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 325-36	5.4	15
40	Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. <i>Journal of Translational Medicine</i> , 2007 , 5, 67	8.5	89
39	Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. <i>Journal of Translational Medicine</i> , 2007 , 5, 68	8.5	25
38	Melanoma cancer vaccines and anti-tumor T cell responses. <i>Journal of Cellular Biochemistry</i> , 2007 , 102, 301-10	4.7	35
37	Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 1931-43	7.4	51
36	AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. <i>Journal of Immunotherapy</i> , 2007 , 30, 425-37	5	45
35	Recent advances in immunotherapy for hepatocellular cancer. <i>Swiss Medical Weekly</i> , 2007 , 137, 83-90	3.1	28
34	Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. <i>Journal of Immunology</i> , 2006 , 177, 712-21	5.3	60
33	A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. <i>Clinical Cancer Research</i> , 2006 , 12, 2817-25	12.9	183
32	Activation of antigen-presenting cells by DNA delivery vectors. <i>Expert Opinion on Biological Therapy</i> , 2005 , 5, 1019-28	5.4	15
31	Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. <i>Cancer Gene Therapy</i> , 2005 , 12, 516-27	5.4	25
30	Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. <i>Journal of Immunology</i> , 2004 , 173, 2462-9	5.3	94

29	Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. <i>Journal of Immunology</i> , 2004 , 172, 4762-9	5.3	18
28	Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. <i>Immunology</i> , 2004 , 113, 472-81	7.8	18
27	Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. <i>Contemporary Clinical Trials</i> , 2004 , 25, 400-7		5
26	Immunotherapeutic strategies for hepatocellular carcinoma. <i>Gastroenterology</i> , 2004 , 127, S232-41	13.3	80
25	Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. <i>Journal of Immunotherapy</i> , 2004 , 27, 354-67	5	100
24	Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. <i>Journal of Immunotherapy</i> , 2004 , 27, 191-200	5	55
23	Current developments in cancer vaccines and cellular immunotherapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2415-32	2.2	254
22	Determinant spreading and tumor responses after peptide-based cancer immunotherapy. <i>Trends in Immunology</i> , 2003 , 24, 58-61	14.4	92
21	Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. <i>Clinical Cancer Research</i> , 2003 , 9, 998-1008	12.9	177
20	Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. <i>Cancer Research</i> , 2003 , 63, 5607-14	10.1	24
19	T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 5902-8	12.9	116
18	Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. <i>Cancer Gene Therapy</i> , 2002 , 9, 875-83	5.4	12
17	Rational design of peptide-based tumor vaccines. <i>Pharmaceutical Research</i> , 2002 , 19, 926-32	4.5	6
16	Immunotherapy of hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2002 , 2, 123-33	5.4	18
15	Cancer immunotherapy using gene-modified dendritic cells. <i>Current Gene Therapy</i> , 2002 , 2, 57-78	4.3	64
14	DNA and Dendritic Cell-Based Genetic Immunization Against Cancer 2002 , 179-198		
13	T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. <i>Journal of Immunology</i> , 2001 , 166, 5300-8	5.3	117
12	Genetic immunotherapy for cancer. <i>Oncologist</i> , 2000 , 5, 87-98	5.7	21

11	Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. <i>Molecular Immunology</i> , 2000 , 37, 943-50	4.3	45
10	Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. <i>Human Gene Therapy</i> , 2000 , 11, 53-65	4.8	106
9	Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. <i>Journal of Immunotherapy</i> , 2000 , 23, 59-66	5	57
8	Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. <i>Cancer Gene Therapy</i> , 1999 , 6, 523-36	5.4	30
7	From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. <i>Antioxidants and Redox Signaling</i> , 1999 , 1, 385-402	8.4	119
6	In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. <i>Human Gene Therapy</i> , 1997 , 8, 2173-82	4.8	80
5	Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions. <i>Gene</i> , 1997 , 191, 129-34	3.8	21
4	Antioxidant function of recombinant human natural killer enhancing factor. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 208, 964-9	3.4	76
3	Cloning and sequence analysis of candidate human natural killer-enhancing factor genes. <i>Immunogenetics</i> , 1994 , 40, 129-34	3.2	95
2	Human Tumor Antigens as Targets of Immunosurveillance and Candidates for Cancer Vaccines	23-43	3
1	Cancer and the Immune System	573-591	1